St. Olavs Hospital
Trondheim, Norway
17 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Acute Myeloid Leukemia
University of Ulm650 enrolled91 locationsNCT04628026
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled261 locationsNCT05552222
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled129 locationsNCT07222332
Recruiting
Phase 3
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis+1 more
Eli Lilly and Company150 enrolled63 locationsNCT04844606
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 1Phase 2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Celgene62 enrolled22 locationsNCT06988488
Recruiting
Not Applicable
RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3
Radiotherapy Side EffectHead and Neck Cancer
Oslo University Hospital100 enrolled3 locationsNCT06297902
Recruiting
Phase 3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Janssen Research & Development, LLC120 enrolled79 locationsNCT05923073
Recruiting
Phase 3
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology160 enrolled112 locationsNCT05327894
Recruiting
Phase 3
Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
Prostate Cancer
Sven Löffeler980 enrolled18 locationsNCT05448547
Recruiting
Phase 2
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
Metastatic Colorectal CancerFirst-line TreatmentOrganoids+3 more
St. Olavs Hospital148 enrolled1 locationNCT06907342
Recruiting
Phase 2Phase 3
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Multiple Myeloma
Oslo University Hospital176 enrolled13 locationsNCT04513639
Recruiting
Phase 2
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Multiple Myeloma
North Estonia Medical Centre50 enrolled7 locationsNCT06505369
Recruiting
Phase 2
A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS)
Fundació Sant Joan de Déu364 enrolled7 locationsNCT05394142
Recruiting
The Norwegian Antirheumatic Drug Register
Inflammatory Joint Diseases
Diakonhjemmet Hospital15,000 enrolled6 locationsNCT01581294
Recruiting
Not Applicable
Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
Prostatic Neoplasms
Olof Akre1,200 enrolled30 locationsNCT02102477